A Phase 3, Randomized, Controlled, Double-Masked, Multi-Center, Comparative, In Parallel Groups (For 24 Weeks), To Compare The Efficacy And Safety of 0.3 mg Pegaptanib Sodium, With Sham Injections, and Open Study (for 30 Weeks) to Confirm the Safety of 0.3 mg Pegaptanib Sodium in Subjects With Diabetic Macular Edema (Dme).

Trial Profile

A Phase 3, Randomized, Controlled, Double-Masked, Multi-Center, Comparative, In Parallel Groups (For 24 Weeks), To Compare The Efficacy And Safety of 0.3 mg Pegaptanib Sodium, With Sham Injections, and Open Study (for 30 Weeks) to Confirm the Safety of 0.3 mg Pegaptanib Sodium in Subjects With Diabetic Macular Edema (Dme).

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2013

At a glance

  • Drugs Pegaptanib (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jun 2012 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 25 May 2012 Status changed from active, no longer recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top